Dissertations / Theses on the topic 'Anticoagulants'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 dissertations / theses for your research on the topic 'Anticoagulants.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse dissertations / theses on a wide variety of disciplines and organise your bibliography correctly.
Lloret, Dominique. "Les anticoagulants circulants spontanés anti facteur VIII:c. à propos d'un cas." Montpellier 1, 1989. http://www.theses.fr/1989MON11228.
Full textLlory, Pierre. "Actualité sur les anticoagulants circulants antithrombinase : incidences en anesthésie-réanimation." Montpellier 1, 1988. http://www.theses.fr/1988MON11372.
Full textMoustafa, Farès. "Risque hémoragique sous anticoagulants : Vers une prise en charge personnalisée." Thesis, Lyon, 2017. http://www.theses.fr/2017LYSES049/document.
Full textIntroduction. Given many risk factors that may influence the risk of hemorrhage underanticoagulant therapy, the concept of personalized medicine could have a favorableimpact in the overall management of these patients.Hypothesis and objective. The hypothesis of this thesis is that the use and analyze of "reallife" registries could allow to define hemorrhagic "profiles" allowing a personalizedmanagement of the patients.Material and method. This thesis work has used two real life registries, the RIETE registry(international, multicentric and prospective register) and RATED (monocentric register).Results. We showed the importance of biological database in the analysis of hemorrhagicevents under anticoagulants with a higher loss of coagulation factors in gastrointestinalbleeding compared with intracranial bleeding under AVK. Conversely, this bleeding risk istwo times lower in case of factor V Leiden mutation. Thanks to the RIETE registry, wewere interested in abnormal uterine bleeding under anticoagulant therapy (few studies inthe literature) with major uterine bleeding only for 0.17% of women. Then, we showed thatfragile patients (CrCl ≤50 mL / min, age ≥75 years or body weight ≤50 kg) have a 2-foldhigher risk for major bleeding. Finally, in order to show the complementarity between datafrom real life registries and randomized trial, we assessed patients normally excluded fromthese randomized trials and also showed a 4-fold higher bleeding risk in these excludedpatients.Conclusion. This thesis work allowed us to demonstrate the interest of working not only onoverall hemorrhages but on each type of hemorrhage separately, with a particular interestto create real life prospective registries with the implementation of bio-bank allowing amore personalized analysis of the intake of patients
Mehta, Akul. "Synthetic, Sulfated, Lignin-Based Anticoagulants." VCU Scholars Compass, 2014. http://scholarscompass.vcu.edu/etd/598.
Full textHababou, Karine. "Les traitements de la maladie thromboembolique : intérêt de l'international normalized ratio (INR) pour leur surveillance." Paris 5, 1991. http://www.theses.fr/1991PA05P089.
Full textCampos, Nelson Leonardo Kerdahi Leite de [UNESP]. "Análise do controle de anticoagulação oral em pacientes portadores de próteses valvares cardícas mecânicas por meio de ambulatório especializado: experiência de 10 anos." Universidade Estadual Paulista (UNESP), 2006. http://hdl.handle.net/11449/100384.
Full textFundação para o Desenvolvimento Médico e Hospitalar (Famesp)
Estudo realizado, com base nos dados do ambulatório, para controle de anticoagulação nos pacientes portadores de próteses valvares cardíacas mecânicas do Serviço de Cirurgia Cardiovascular do Hospital das Clínicas da Faculdade de Medicina de Botucatu, no intervalo de dez anos, com os objetivos: avaliação da resposta à terapêutica profilática anticoagulante; quantificação das complicações tromboembólicas e hemorrágicas, com estratificação de sua gravidade; comparação entre tipos de anticoagulantes orais, doses e efeitos; influência da posição da prótese; presença de fibrilação atrial e tamanho do átrio esquerdo; e análise da estratégia de anticoagulação adotada. Foram incluídos, no estudo, 259 pacientes portadores de próteses mitrais (mitrais), aórticas (aórticos) e mitral e aórticas (mitro-aórticos). Foram analisadas 9714 consultas com valores do tempo de protrombina (em RNI) e dados dos registros hospitalares sobre complicações tromboembólicas e hemorrágicas com graus de gravidade. Os pacientes foram divididos em quatro grupos de acordo com o porcentual de consultas em que a RNI se encontrava dentro do intervalo desejado. Foram estudados dois anticoagulantes (Fenprocumona e Warfarina) e suas dosagens. Foi, também, avaliada a ocorrência de complicações tromboembólicas e hemorrágicas. Os resultados estão apresentados em: número de pacientes com complicações, estudo atuarial e freqüência linearizada de ocorrência de eventos. Os dados obtidos permitiram concluir que: a anticoagulação oral foi mais satisfatória nos aórticos do que nos mitrais e mitro-aórticos; os mitrais apresentaram ocorrência de eventos tromboembólicos semelhante a dos aórticos, porém com maior freqüência de hemorragias; os grupos que tiveram anticoagulação mais estável apresentaram menos complicações; poucas diferenças quanto à ocorrência de...
The study was held using outpatient data collected during 10 years for anticoagulation control of patients with mechanical prosthetic heart valves from the Cardiovascular Surgery Service at the Medical University Hospital in Botucatu city. The objectives were as follows: evaluation of prophylactic anticoagulation therapy, number of thromboembolic and hemorrhagic complications and their severity stratification, assessment of different oral anticoagulants, their effects and dosing, influence of prosthesis position, presence of atrial fibrillation and size of the left atrium, assessment of the anticoagulation strategy. Two hundred and fifty nine patients with mitral (M), aortic (A), mitral and aortic (M-A) prostheses were included in the study. Prothrombin time expressed in terms of international normalised ratio (INR) from 9714 consultations, medical data on thromboembolic and hemorrhagic complications as well as their severity were evaluated. Patients were allocated to four groups according to percentage of consultations which INR was within the target range. Two anticoagulants (Fenprocoumon and Warfarin), their dosing system, thromboembolic and hemorrhagic complications were also evaluated. Results were expressed as: number of patients with complications, actuarial study and linearized rate of events. Conclusions: oral anticoagulation was better in A than in M or M-A patients; M patients presented as many thromboembolic events as A patients although with higher hemorrhagic rate; groups presenting more steady anticoagulation showed fewer complications; there were few differences concerning complications among users of Fenprocoumon and Warfarin; most patients needed lower anticoagulant doses; patients with atrial fibrillation and/or enlarged left atrium presented as many thromboembolic complications as the other studied patients, although with higher... (Complete abstract click electronic access below)
Barrière, Véronique. "Présence d'un anticoagulant circulant chez un insuffisant rénal chronique." Montpellier 1, 1989. http://www.theses.fr/1989MON11217.
Full textPham, Thuy-Hang. "Thérapeutique anticoagulante dans un service de cardiologie : prescription et suivi thérapeutique." Paris 5, 1991. http://www.theses.fr/1991PA05P050.
Full textMueller, Tanja. "Use of direct oral anticoagulants in Scotland." Thesis, University of Strathclyde, 2017. http://digitool.lib.strath.ac.uk:80/R/?func=dbin-jump-full&object_id=28882.
Full textFONDO, JASKIEWICZ MARTINE. "Intoxications secondaires a l'ingestion de raticides anticoagulants." Reims, 1994. http://www.theses.fr/1994REIMM082.
Full textRaucourt, Perthuis Emmanuelle de. "Etude de polysaccharides sulfatés anticoagulants : Texte imprimé." Paris 13, 1997. http://www.theses.fr/1997PA132017.
Full textBossaer, John B., and Kelly L. Covert. "Direct Oral Anticoagulants in Patients with Cancer." Digital Commons @ East Tennessee State University, 2019. https://dc.etsu.edu/etsu-works/7793.
Full textSantana, Ana Paula Bagesteiro. "AVALIAÇÃO DE PACIENTES AMBULATORIAIS EM USO DE ANTICOAGULANTES ORAIS." Universidade Federal de Santa Maria, 2006. http://repositorio.ufsm.br/handle/1/5871.
Full textAs doenças trombóticas constituem um problema de saúde mundial de etiologia multifatorial e multigênica. São caracterizadas por formação aguda de trombos em veias e artérias. Os anticoagulantes orais são usados para criar uma deficiência parcial da forma ativa da vitamina K, um cofator na modificação dos fatores da coagulação vitamina K-dependentes e, assim, reduzir o risco de uma coagulação anormal. Os fármacos antivitamina K ou anticoagulantes orais impedem a carboxilação dos fatores II, VII, IX e X da coagulação, levando à síntese de fatores inativos. Uma série de substâncias pode alterar a ação dos anticoagulantes orais, reduzindo sua ação e aumentando o risco trombótico ou aumentando sua atividade e elevando o risco de sangramento. O controle laboratorial da anticoagulação oral é feito através do Tempo de Protrombina (TP) e do Tempo de Tromboplastina Parcial (TTP), os quais são responsáveis pelo sucesso e segurança deste procedimento terapêutico. Neste trabalho, foram analisados os parâmetros relativos ao acompanhamento ambulatorial de pacientes em uso de anticoagulantes orais e a interferência destes na atividade do fármaco em questão, buscando, dessa forma, uma melhor segurança para este tipo de tratamento. Observo-se que grande parte dos pacientes fazia uso de uma dieta bastante rica em vitamina K, o que acarretava variações nos valores de suas Razões Normalizadas Internacionais (INRs) e, com isso, uma dificuldade maior em encontrar a dose adequada do medicamento para cada paciente. Também se pode concluir que a resposta dos anticoagulantes é influenciada por alguns fatores e estes devem ser considerados como, por exemplo, o uso de outros medicamentos que afetem a liberação ou absorção do fármaco, problemas técnicos de laboratório e a variabilidade individual de cada paciente frente ao medicamento.
Campos, Nelson Leonardo Kerdahi Leite de. "Análise do controle de anticoagulação oral em pacientes portadores de próteses valvares cardícas mecânicas por meio de ambulatório especializado : experiência de 10 anos /." Botucatu : [s.n.], 2006. http://hdl.handle.net/11449/100384.
Full textResumo: Estudo realizado, com base nos dados do ambulatório, para controle de anticoagulação nos pacientes portadores de próteses valvares cardíacas mecânicas do Serviço de Cirurgia Cardiovascular do Hospital das Clínicas da Faculdade de Medicina de Botucatu, no intervalo de dez anos, com os objetivos: avaliação da resposta à terapêutica profilática anticoagulante; quantificação das complicações tromboembólicas e hemorrágicas, com estratificação de sua gravidade; comparação entre tipos de anticoagulantes orais, doses e efeitos; influência da posição da prótese; presença de fibrilação atrial e tamanho do átrio esquerdo; e análise da estratégia de anticoagulação adotada. Foram incluídos, no estudo, 259 pacientes portadores de próteses mitrais (mitrais), aórticas (aórticos) e mitral e aórticas (mitro-aórticos). Foram analisadas 9714 consultas com valores do tempo de protrombina (em RNI) e dados dos registros hospitalares sobre complicações tromboembólicas e hemorrágicas com graus de gravidade. Os pacientes foram divididos em quatro grupos de acordo com o porcentual de consultas em que a RNI se encontrava dentro do intervalo desejado. Foram estudados dois anticoagulantes (Fenprocumona e Warfarina) e suas dosagens. Foi, também, avaliada a ocorrência de complicações tromboembólicas e hemorrágicas. Os resultados estão apresentados em: número de pacientes com complicações, estudo atuarial e freqüência linearizada de ocorrência de eventos. Os dados obtidos permitiram concluir que: a anticoagulação oral foi mais satisfatória nos aórticos do que nos mitrais e mitro-aórticos; os mitrais apresentaram ocorrência de eventos tromboembólicos semelhante a dos aórticos, porém com maior freqüência de hemorragias; os grupos que tiveram anticoagulação mais estável apresentaram menos complicações; poucas diferenças quanto à ocorrência de... (Resumo completo, clicar acesso eletrônico abaixo)
Abstract: The study was held using outpatient data collected during 10 years for anticoagulation control of patients with mechanical prosthetic heart valves from the Cardiovascular Surgery Service at the Medical University Hospital in Botucatu city. The objectives were as follows: evaluation of prophylactic anticoagulation therapy, number of thromboembolic and hemorrhagic complications and their severity stratification, assessment of different oral anticoagulants, their effects and dosing, influence of prosthesis position, presence of atrial fibrillation and size of the left atrium, assessment of the anticoagulation strategy. Two hundred and fifty nine patients with mitral (M), aortic (A), mitral and aortic (M-A) prostheses were included in the study. Prothrombin time expressed in terms of international normalised ratio (INR) from 9714 consultations, medical data on thromboembolic and hemorrhagic complications as well as their severity were evaluated. Patients were allocated to four groups according to percentage of consultations which INR was within the target range. Two anticoagulants (Fenprocoumon and Warfarin), their dosing system, thromboembolic and hemorrhagic complications were also evaluated. Results were expressed as: number of patients with complications, actuarial study and linearized rate of events. Conclusions: oral anticoagulation was better in A than in M or M-A patients; M patients presented as many thromboembolic events as A patients although with higher hemorrhagic rate; groups presenting more steady anticoagulation showed fewer complications; there were few differences concerning complications among users of Fenprocoumon and Warfarin; most patients needed lower anticoagulant doses; patients with atrial fibrillation and/or enlarged left atrium presented as many thromboembolic complications as the other studied patients, although with higher... (Complete abstract click electronic access below)
Doutor
Sanchez-Peña, Paola. "Analyse du rapport bénéfice/risque des traitements antithrombotiques, influence de la variabilité du niveau d'anticoagulation sur les risques thrombo-embolique et hémorragique." Paris 5, 2005. http://www.theses.fr/2005PA05P611.
Full textCasamira, i. Ruiz Núria. "Avaluació de l’efectivitat i la seguretat dels anticoagulants orals d'acció directa en pacients amb fibril·lació auricular sotmesos a intervencionisme coronari percutani amb implantació d'stent." Doctoral thesis, Universitat de Barcelona, 2020. http://hdl.handle.net/10803/671149.
Full textTriple antithrombotic therapy (TT) is recommended for patients with non-valvular atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI). However, there is a lack of comparative data in a real-world clinical setting between patients receiving TT with direct oral anticoagulants (DOAC) and patients receiving TT with Vitamin K antagonists (VKA). The aim of this thesis was to compare the safety and efficacy of TT with DOAC or VKA after PCI in patients with AF at 1-year of follow-up. We designed an observational retrospective study in two tertiary care hospitals during 2013-2016. A total number of 187 consecutive with an indication for anticoagulation due to AF from an initial registry of 5,269 patients undergoing PCI were identified: 85 were discharged on TT with NOAC and 102 were discharged on TT with VKA. The primary safety endpoint was the occurrence of total bleeding events at 12 months, which was found to be significantly lower in the DOAC group compared with the VKA group (12.9% in DOAC vs 31.4% in VKA, adjusted HR, 0.39; 95% CI, 0.19 – 0.83, P = 0.014). The primary efficacy endpoint was the rate of major adverse cardiovascular events (MACE) which occurred in 16.5% of patients treated with DOAC and 22.5% of patients treated with VKA, with no significant differences between groups (adjusted HR, 0.67; 95% CI, 0.33–1.37, P = 0.273). This is the first study in a real-world population comparing the efficacy and safety of the use of TT with either DOAC or AVK in patients with AF undergoing PCI. The results provide signal of lower bleeding rates and similar efficacy of DOACs as compared to VKA, shedding light into this field by providing real-world comparison data of DOAC vs VKA.
Persson, Anna. "Non-vitamin K dependent oral anticoagulants (NOACs) controls." Thesis, Linköpings universitet, Institutionen för fysik, kemi och biologi, 2018. http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-148558.
Full textRENOUF, PASCALE. "Anticoagulants et accidents du travail : aspects medico-legaux." Nantes, 1994. http://www.theses.fr/1994NANT023M.
Full textAbohelaika, Salah Ahmed O. "Factors affecting the safe use of oral anticoagulants." Thesis, University of Newcastle upon Tyne, 2017. http://hdl.handle.net/10443/3859.
Full textAttias, Nathalie. "Résistance au traitement par les antivitamines K." Paris 5, 1999. http://www.theses.fr/1999PA05P126.
Full textImrith, Vishwamitr. "Anticoagulants circulants et maladies infectieuses : à propos d'un cas rencontré au cours d'un paludisme à Plasmodium falciparum." Bordeaux 2, 1989. http://www.theses.fr/1989BOR25190.
Full textMatthíasson, Stefán E. "Low molecular weight heparin and dextran in thromboprophylaxis human and experimental studies /." Malmö : Dept. of Surgery, Lund University, Malmö General Hospital, 1994. http://books.google.com/books?id=9OxsAAAAMAAJ.
Full textLefebvre, Sébastien. "Étude de l'impact du sexe sur la coagulation vitamine K dépendante chez le rat." Thesis, Lyon, 2016. http://www.theses.fr/2016LYSE1231/document.
Full textVitamin K antagonists (VKA) are inhibitors of the recycling mechanism of vitamin K. Vitamin K is involved in the post-translational activation by gamma-carboxylation of vitamin K dependant proteins, and in particular four proteins essential to coagulation. Food intake of vitamin K is insufficient to substitute the recycling mechanism, an efficient cycle is necessary. If VKA block the recycling mechanism, gamma-caboxylation of vitamin K dependant clotting factors becomes is not done, thus the production of the active form of these clotting factors is diminished. Consequently, the blood coagulability is affected. An important inhibition of the recycling mechanism can kill by haemorrhage, it’s with this aim that VKA are used in rodent management. Over the past three decades, a slight resistance to VKA has been observed in female rats beside male rats. Some hypothesis can explain this difference: (i) a more efficient activity of female microsomes which are responsible of the vitamin K regeneration; (ii) a faster elimination of VKA in female rats; (iii) basal concentrations and half-lives of vitamin K dependant clotting factors are higher in female rats. The main purpose of this work is to identify the origin of the resistance of female rats to VKA.Our results pinpoint significant differencies between females and males concerning the basal levels and the evolution kinetics of some vitamin K dependant clotting factors. This might explain the weaker sensibility of female rats to VKA
Manero, Florence. "Étude de deux voies de modulation de l'apoptose : l'inhibition de l'apoptose par la petite protéine de stress Hsp27 et la stimulation par des anticoagulants de l'apoptose dépendante du récepteur Fas." Lyon 1, 2003. http://www.theses.fr/2003LYO10092.
Full textDa, Silva Éric. "Calix-[n]-arènes sulfonates : propriétés complexantes et anti-coagulantes." Lyon 1, 2003. http://www.theses.fr/2003LYO10251.
Full textBrunie, Vanida. "Education thérapeutique des patients traités par anticoagulants oraux (AVK) : problématiques didactique et organisationnelle : Contribution à l’élaboration d’un modèle d’éducation thérapeutique." Thesis, Sorbonne Paris Cité, 2015. http://www.theses.fr/2015USPCD093.
Full textThe VKA treatment concerns more than 1% of the french population. It represents a major public health problem beacause of its consirable drug related iatrogny
Javed, Najma H. "Effects of lupus anticoagulants on thrombosis-related endothelial function." Virtual Press, 1987. http://liblink.bsu.edu/uhtbin/catkey/483176.
Full textMorin, Sandrine. "La pharmacogénétique du type CYP2C9 et des anticoagulants oraux." Paris 5, 2003. http://www.theses.fr/2003PA05P607.
Full textCytochrome P450 2C9 (CYP2C9) metabolises 20 % of drugs and is involved in the metabolism of molecules with narrow therapeutic index: warfarin (antagonist of the vitamin K, AVK), acenocoumarol (AVK). CYP2C9 is genetically polymorphique. Two alleles CYP2C9*2 and CYP2C9*3 affect doses of warfarin. Patients carrying one of these alleles (poor metabolisers, PM) have significantly lower doses of AVK (warfarin, acenocoumarol) than patients without these mutations. There is no phenotyping test to identify PM. We tried to establish a phenotyping test using diclofenac then acenocoumarol. None of these drugs agrees for pharmacokinetic reasons (diclofenac) or for the great interindividual variability of the acenocoumarol pharmacodynamic answer. But our works show that the CYP2C9*3 allele under its homozygous shape increases the acenocoumarol pharmacodynamic answer and is responsible for overdoses in oral anticoagulants. It is useless to research CYP2C9*3 in the Asian population because of its rarity. CYP2C9 alleles explains only a part of the interindividual variability of the pharmacodynamic answer to oral anticoagulants
Henry, Brian Lawrence. "Novel Sulfated 4-Hydroxycinnamic Acid Oligomers as Potent Anticoagulants." VCU Scholars Compass, 2007. http://scholarscompass.vcu.edu/etd/1462.
Full textVerespy, Stephen S. III. "Probing Allosteric, Partial Inhibition of Thrombin Using Novel Anticoagulants." VCU Scholars Compass, 2016. http://scholarscompass.vcu.edu/etd/4431.
Full textBatista, Saulo Hilton Botelho. "Evaluation of the use of different local hemostatics procedures to manage post extraction bleeding in patients under anticoagulation treatment." Universidade Federal do CearÃ, 2010. http://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=6328.
Full textThe therapeutic use of Varfarin, the most common oral anticoagulant it is indicated in many cases, including the atrial fibrillation, cardiac valvular prostheses and venous trombolic disease. Many discussions still exist related to the suspension or not before tooth extraction. People who are for itâs suspension agree that it may increase the risk of hemorrhage, however the ones who prefer to maintain itâs use refer the high risk of tromboembolism. Due to the controversy related to the cronic use of oral anticoagulant before tooth extraction and what to use to control bleeding after extraction, we decided to perform a one center randomized clinical trial study to compare the effectiveness of the hemostasis using soaked gauze with tranexamic acid at 4,8% and plain gauze and the use of collagen sponge (HemosponÂ), using it inside the tooth socket after extraction. The sample was made of 84 surgical procedures performed in 38 patients who were under anticoagulant treatment and who needed at least one tooth extraction. The trial was divided in three groups regarding the method used to reach hemostasis after tooth extraction. In group I we used compression with soaked gauze with tranexamic acid at 4,8%; in group II we used collagen sponge (HemosponÂ) inside the socket while in group III we compressed the socket with dry gauze for 8 minutes. There were two cases of post surgical bleeding, being one from group I and one from group II. The data collected was evaluated thru SPSS 1.5 (Statistic Package of Social Science) program. All the statistical analysis performed were considered significantly when p was less than 5%. We used the Qui square X2 Test, Fisher Exact Test e Analysis of Variance (ANOVA) to verify the variables of the data. There was no statistically significant difference between the groups, related to bleeding (p>0,05). The compression with dry gauze and suture, compression with soaked gauze with trenaxamic acid at 4.8% and suture and the use of collagen sponge (HemosponÂ) in the tooth socket hold with suture showed similar efficacy to the control of post extraction bleeding in patients who are under anticoagulant treatment.
A terapÃutica com varfarina, o anticoagulante oral mais utilizado, està indicada em mÃltiplas situaÃÃes, incluindo a fibrilaÃÃo atrial, prÃteses valvulares cardÃacas e o tromboembolismo venoso. DiscussÃes ainda existem sobre a indicaÃÃo ou nÃo da sua interrupÃÃo prÃvia a realizaÃÃo de exodontias. Aqueles que defendem a parada de sua administraÃÃo baseiam tal decisÃo no risco aumentado de hemorragias, enquanto os que acreditam na manutenÃÃo da terapia ressaltam o risco de tromboembolismo. Em virtude das controvÃrsias acerca da realizaÃÃo de exodontias em pacientes que fazem uso crÃnico de anticoagulantes orais, alÃm da dÃvida de que mÃtodo empregar no controle do sangramento pÃs-exodontia, decidimos realizar um estudo do tipo ensaio clÃnico, unicÃntrico, randomizado com o objetivo de comparar a efetividade hemostÃtica local da compressÃo com gaze embebida ou nÃo em Ãcido tranexÃmico à 4,8% com o emprego da esponja de colÃgeno (HEMOSPONÂ) no interior do alvÃolo pÃs-exodontia. A amostra foi constituÃda por 84 procedimentos cirÃrgicos realizados em 38 pacientes sob terapia anticoagulante que necessitavam de pelo menos uma extraÃÃo dentÃria. A amostra foi dividida em trÃs grupos a depender do mÃtodo hemostÃtico local empregado para o controle do sangramento apÃs a extraÃÃo dentÃria. No grupo I utilizou-se a compressÃo com gaze embebida em Ãcido tranexÃmico a 4,8%; no grupo II introduziu-se no interior do alvÃolo uma esponja de colÃgeno (HemosponÂ); enquanto no grupo III, a compressÃo com gaze seca por 8 minutos foi o mÃtodo empregado. Em dois casos foi observado sangramento pÃs-operatÃrio sendo um paciente do grupo I e outro do grupo II. Os dados coletados foram consolidados e avaliados por meio do programa SPSS 15.0 (Statistic Package of Social Science). Todas as anÃlises estatÃsticas efetuadas foram consideradas significativas quando valor de p foi menor que 5%. Utilizou-se os testes Qui-Quadrado (XÂ), Teste Exato de Fisher e AnÃlise de VariÃncia (ANOVA) para verificar as diferenÃas entre as variÃveis. NÃo houve diferenÃa estatisticamente significante entre os grupos com relaÃÃo à ocorrÃncia de hemorragias (p-valor>0,05). A compressÃo com gaze seca associado à sutura, a compressÃo com gaze embebida com Ãcido tranexÃmico a 4,8% associada a sutura e o emprego da esponja de fibrina (HemosponÂ) intra-alveolar associado a sutura mostraram eficÃcia semelhante no controle do sangramento pÃs-exodontia em pacientes sob terapia anticoagulante.
Guasch, i. Casany Eduard. "Estudi de la Fibril·lació Auricular: de la fisiopatologia al tractament." Doctoral thesis, Universitat de Barcelona, 2012. http://hdl.handle.net/10803/127299.
Full textAtrial fibrilliation is the most common cardiac arrhythmia, with a high morbidity, mortality and economic burden. An aging population in the upcoming years will likely increase its incidence and intensificate its epidemiological importante. This doctoral thesis approaches the pathology and therapy of atrial fibrillation through clinical and experimental studies. Very high intensity exercise is an emerging cause of atrial fibrillation in young and middle-aged individuals. However, its pathophysiology is unknown, yet. Here, a rat model of endurance, very high intensity exercise is used to study its mechanisms. By mean of in vivo and in vitro techniques, vagal enhancement is shown to be key factor in the development of exercise-induced atrial fibrillation. Moreover, exercise-induced arrhythmogenic atrial substrate is reversible, particularly concerning vagal enhancement. In contrast, structural remodeling (atrial fibrosis and dilatation) slowly or uncompletely reversed. MicroRNAs are recently discovered short RNA sequences that regulate post-transcriptional gene expression. MicroRNAs are involved in a large number of physiological and pathological processes, including fibrosis development. However, it is unknown whehter they participate in atrial fibrillation substrate. In this thesis, miR-21 involvement in post-left ventricle myocardial infarction atrial remodeling is explored. A left ventricle myocardial infarction rat model with a high burden of atrial fibrillation inducibility is used. We show that miR-21 is involved in atrial fibrosis pathology, and its inhibition may prevent its development and atrial fibrillation inducibility. Mir-21 is postulated as a potential therapeutic target in the treatment of atrial fibrillation. Anticoagulant therapy is on the basis of thrombo-embolic risk prevention in atrial fibrillation patients. Occasionally, patients diagnosed with atrial fibrillation are also diagnosed of ischemic cardiomyopathy and require antiplatelet therapy with aspirin and tienopiridines. The hemorrhagic risk of triple thrombotic combination of anticoagulation, aspirin and thienopiridines is unknown. In this thesis we study this problem in patients undergoing coronary intervention and show that this occurs in one out of eight patients in the cath lab. At follow-up patients who were prescribed triple combination antithrombotic had a significantly lower incidence of thrombotic events than those who did not receive it. A higher risk of non-serious bleeding balanced its benefits.
Paoli, Michèle. "Les hématomes du muscle psoas iliaque apparus au cours d'un traitement anticoagulant : à propos de sept observations." Bordeaux 2, 1990. http://www.theses.fr/1990BOR25024.
Full textDelouis, Pascale. "Place des anticoagulants dans la prévention et le traitement des accidents thromboemboliques de la grossesse et du post-partum." Bordeaux 2, 1991. http://www.theses.fr/1991BOR23074.
Full textMervelay, Patricia Paille François. "Evaluation de l'éducation du patient traité par antagoniste de la vitamine K en médecine générale en Lorraine." [S.l] : [s.n], 2003. http://www.scd.uhp-nancy.fr/docnum/SCDMED_T_2003_MERVELAY_VERONIQUE.pdf.
Full textFazavana, Judicaël. "Développement d'une antithrombine modifiée inactive comme antidote des anticoagulants hépariniques." Phd thesis, Université Paris Sud - Paris XI, 2012. http://tel.archives-ouvertes.fr/tel-00976551.
Full textFazavana, Judicaël. "Développement d’une antithrombine modifiée inactive comme antidote des anticoagulants hépariniques." Thesis, Paris 11, 2012. http://www.theses.fr/2012PA114855/document.
Full textUnfractionnated heparin (UFH), low molecular weight heparins (LMWH), and fondaparinux are used therapeutically as anticoagulants. They potentiate antithrombin (AT): a physiological inhibitor of coagulation. Their therapeutic use is associated with a major risk of bleeding. Currently, protamine sulfate is the only antidote available for UFH. It is partially effective for LMWH, and has no effect against fondaparinux, which has no antidote. So, we propose modified inactive AT, but able to bind heparin molecules as antidote of these heparins. These molecules would compete with plasmatic AT for binding to heparins, and neutralize their anticoagulant effect. To produce that AT, we realized a genetic approach and a chemical approach. In the first approach, we expressed the variant AT-N135Q-Pro394 that had an anti-Xa or anti-IIa activity below 0.02% in the presence of heparins, and heparin affinity three times higher, compared to the plasmatic AT. In the chemical approach, we modified the plasmatic AT by 2,3-butanedione (AT-BD), a chemical reagent for arginin’s characterization. The AT-BD had a moderate loss of anticoagulant activity, and a heparin affinity 20 times higher, compared to the plasmatic AT. Despite these differences in biochemical properties, these two modified AT neutralize similarly heparins in vitro and in a mouse model. Moreover, unlike protamine sulfate, our antidotes had not an intrinsic anticoagulant effect in activated partial thromboplastin test. Thus, this PhD-work offers the first and the only specific antidote described to fondaparinux, and it can be used too alternatively for all anticoagulant heparins
GOSEK, VERGAN CORINE. "Les complications abdominales des anticoagulants (a l'exclusion des hemorragies digestives)." Aix-Marseille 2, 1989. http://www.theses.fr/1989AIX20346.
Full textMauray, Sandrine. "Activités anticoagulante et antithrombotique de polysaccharides sulfatés." Paris 13, 1995. http://www.theses.fr/1995PA132026.
Full textBarna, Linda Kathern. "A third international survey to study clinical laboratory testing for the lupus anticoagulant." Virtual Press, 1995. http://liblink.bsu.edu/uhtbin/catkey/958796.
Full textCenter for Medical Education
Kesby, Gregory John. "Heparin and cranial neurulation in the rat." Thesis, University of Cambridge, 1992. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.259732.
Full textViguier, Christophe Nogarède Bertrand. "Contribution au développement d'actionneurs électroactifs pour l'assistance circulatoire application à la mise au point d'une fonction antithrombotique /." Toulouse : INP Toulouse, 2006. http://ethesis.inp-toulouse.fr/archive/00000176.
Full textManzato, Rafaela de Oliveira. "Efeito do acompanhamento telefônico na qualidade de vida relacionada à saúde de pacientes nos primeiros seis meses de uso da varfarina: ensaio clínico aleatorizado." Universidade de São Paulo, 2018. http://www.teses.usp.br/teses/disponiveis/83/83131/tde-08112018-151203/.
Full textWarfarin is an oral anticoagulant, antivitamin K, widely used in the prevention of intravascular thrombi of different etiologies. It requires rigorous and complex control as a result of its interaction with other drugs and foods, which may interfere with users\' Quality of Life Related to Health (HRQoL). Educational interventions have been used to lessen the impact of this therapy. The main objective was to compare the HRQoL, at three and six months after discharge, of two groups of patients who started using warfarin for the first time during hospitalization. Secondary objectives, were to compare the presence of anxiety and depression symptoms and the adequacy of the International Normalized Ratio (INR) value in the indicated therapeutic range, between the groups. It is an experimental study with random designation in two groups. The patients in the intervention group (IG) received the educational program with telephone follow-up after discharge and those in the control group (CG) received the educational program without telephone follow-up. The study was approved by the Research Ethics Committee and was enrolled in the ClinicalTrials.gov database. The research was conducted at the State Hospital of Ribeirão Preto and the Hospital Estadual de Américo Brasiliense and included patients who started using warfarin for the first time, over 18 years and with a telephone to contact. The educational program was guided by the Bandura Theory and was composed of verbal and written information about the treatment and approached during hospitalization. GI participants received five telephone contacts to reinforce this information after discharge. Both groups had two face-to-face meetings at three and six months for the evaluation of the outcome variables: HRQOL (assessed by the Brazilian version of the Duke Anticoagulation Satisfaction Scale - DASS) and symptoms of anxiety and depression (assessed by the subscales of Hospital Anxiety and Depression Scale - HADS). To compare the DASS and the HADS scales, we performed Student\'s t-test for independent samples. In order to compare the groups over time, in relation to HRQoL, we performed Variance Analysis (ANOVA) for repeated measures, taking as factors the time (three and six months), the group (intervention or control) and a time interaction per group. The level of significance was set at 0.05. The groups were similar in sociodemographic and clinical characterization. The majority of the participants were married, female and with an average age of 55 years (D.P = 15). The most frequent indications for the initiation of warfarin were deep venous thrombosis and pulmonary thromboembolism. We did not find statistically significant differences between the means of HRQoL, anxiety and depression of the two groups at three and six months after discharge
Pelegrino, Flávia Martinelli. "Avaliação da qualidade de vida relacionada à saúde, adesão ao tratamento medicamentoso e auto eficácia de indivíduos submetidos a um programa educacional após iniciarem o uso de anticoagulante oral." Universidade de São Paulo, 2013. http://www.teses.usp.br/teses/disponiveis/22/22132/tde-25092013-162457/.
Full textOral anticoagulants are drugs that act by increasing blood clotting time and are useful in the presence of certain diseases that lead to the formation of intravascular thrombi. Thus, constant controls of blood levels are necessary for a safe treatment. Some strategies such as educational intervention are showing good results. The main objective of the present study was to assess the quality of life related to health, adhesion to treatment and self-efficacy of patients who had started the use of oral anticoagulants according to the participation in an educational program (Intervention Group) or receiving routine care (Control Group). Secondary objectives were to compare the health status perceived and the presence of anxiety and depression symptoms between groups. This was an experimental study of random design conducted on two groups (Intervention and Control). The Research Ethics Committee approved the study, which was registered in the ClinicalTrials.gov database, and all subjects gave written informed consnet to participate. The study was conducted at the State Hospital of Ribeirão Preto and included patients who had started the use of oral anticoagulants for clinical treatment for the first time, who were older than 18 years and who had adequate cognitive function. The subjects were stratified and randomized using the Outpatient Bleeding Risk Index and by block, respectively. Colored envelopes were used for group allotment. The educational program was based on Bandura\'s theory and consisted of verbal and written information about the treatments applied during hospitalization and of telephone contacts for the reinfordcement of this information during the first and fourth weeks after hospital discharge of the patient. The following instruments were applied during data collection: sociodemographic and clinical characterization, Duke Anticoagulation Satisfaction Scale, Measurements of Adhesion to Treatment, Hospital Anxiety and Depression Scale, and Visual Analogue Scale. The analyses were carried out using the IBM Statistical Package for the Social Sciences (SPSS) version 21.0. Descriptive analyses of simple frequency, position and dispersal were performed. The unpaired Student t-test was used to compare the variables between groups, and the Chi-square or Student t-test was used to compare the frequency of anxiety and depression symptoms, while the paired Student t-test or the non-parametric Wilcoxon test was used to compare the variables at the beginning and at the end of the study in each group. The Chi-square test was applied to compare anxiety and depression before and after the study in each group. The levels of significance was set at 5%. Group comparison showed similar characteristics, a majority of women who were married and aged close to 60 years, and atrial fibrillation or deep venous thrombosis as the indication of the use of an oral anticoagulant. The Intervention Group showed better quality of life related to health, greater adhesion, and more self-efficacy when receiving the new treatment, a fact that possibly reflected lower anxiety and depression compared to the Control Group. We conclude that the participation in an educational program provided better outcomes compared to patients who received routine care.
Bergmann, Carl W. "Studies on the anticoagulant determinants of heparin /." The Ohio State University, 1986. http://rave.ohiolink.edu/etdc/view?acc_num=osu1487268021748443.
Full textTolrà, Rovira Roser. "Nova síntesi d'interès industrial d'un fàrmac genèric." Doctoral thesis, Universitat de Barcelona, 2017. http://hdl.handle.net/10803/462952.
Full textThe main objective of this Thesis was to obtain a novel and alternative route to the existing key intermediate 1 in the synthesis of an anticoagulant drug. The new approach had to be innovative and patentable in order to produce the product industrially. First of all, we searched in the literature the existing synthetic precedents and from these we proposed a series of more specific objectives: a first approach to synthesize the central cyclohexane, another based on a iodolactamization reaction, having one of the nitrogens in the cis-diamino system already introduced, and a third approach based on aziridine as a key intermediate, in this case it has also already one of the nitrogens present in the molecule. The first approach was based on a Diels-Alder reaction as a key step to form the central cyclohexane target molecule. Despite reaching an advanced intermediate, this approach failed to reach the final product and had to discard it. The second route that was tested had a iodolactamization reaction as a key step and followed the synthesis of the Boc derivative of this product . From this intermediate we proposed several alternatives to replace the iodine atom and introduce the second nitrogen in the molecule, either directly with ammonia for example, or through a synthetic equivalent of the amino group for example with an azide or a phthalimide group. We also tried to form an urea intermediate with isocyanate and thus insert the second nitrogen in the six member ring intramolecularly. Unfortunately none of the methods allowed us to arrive at the desired product so we kept on studying the latest approach. The third proposed route passes through a key aziridine intermediate that was formed by the reaction of an olefin with a sulfamide using rhodium catalysts. After testing the main reaction from different substrates, we found a lactone intermediate which was key in this approach. Following a series of simple reactions starting from the lactone we get the objective molecule 1. The main objective was achieved, unfortunately, due to a claim of a patent that protects the last intermediate synthesis and transformation of this to 1, it will not be possible to synthesize 1 industrially following this new process. However, we decided to follow the reactions of the approach that had yielded 1, but varying the dimethylamide group to other alternative groups. We thought about forming activated esters with 2,2,2-trifluoroethanol, phenol and N,N- diethylhydroxylamine. This strategy would reach the target molecule obtained without infringing the patent because it was in the last stage, where it would introduce the dimethylamide group so the route would not pass through the intermediate claimed.
Maistre, Emmanuel de. "Anticoagulants lupiques et anticorps antiphospholipides : comparaison de tests biologiques de detection." Nancy 1, 1993. http://www.theses.fr/1993NAN11021.
Full textJOMIN, MESUROLLE CORINNE. "Les anticoagulants circulants antifacteur viiic : a propos de 3 cas cliniques." Reims, 1990. http://www.theses.fr/1990REIMM006.
Full textSmith, Tracy L. "The Effect of Anticoagulants on White Blood Cell L-selectin Levels." Youngstown State University / OhioLINK, 1998. http://rave.ohiolink.edu/etdc/view?acc_num=ysu997725968.
Full textVilaseca, Barceló Marina. "Mecanismes involucrats en la regulació de la resistència vascular intrahepàtica en la cirrosi: paper dels anticoagulants i antioxidants." Doctoral thesis, Universitat de Barcelona, 2016. http://hdl.handle.net/10803/482197.
Full textThe present doctoral thesis is focused in the development of new therapeutical strategies for the treatment of portal hypertension, one of the main complications of cirrhosis. Increase in portal pressure is directly related to the increased intrahepatic vascular resistance, mainly due to increased vascular tone and increased hepatic fibrosis. Therefore, the main objective of the present doctoral thesis was to study the use of the anticoagulants enoxaparin and rivaroxaban, and the mitochondrial-directed antioxidant mitoquinone and to evaluate their effects on intrahepatic vascular resistance and portal pressure in preclinical models of cirrhosis with portal hypertension. On the one hand, the results of the present doctoral thesis concluded that the anticoagulants, both the anti-thrombin like enoxaparin and the anti-factor Xa (thrombin-independent) rivaroxaban significantly improve portal pressure of animals with cirrhosis and portal hypertension mainly due to improved vascular tone and hepatic fibrosis. On the other hand, we observed that mitochondrial oxidative stress was increased in cirrhotic livers and hepatocytes and hepatic stellate cells were the main cells producing mitochondrial oxidative stress. Furthermore, we confirmed the beneficial effects of antioxidants on cirrhosis. The results concluded that the mitochondrial-directed antioxidant mitoquinone decreased significantly portal pressure and intrahepatic vascular resistance. Moreover, an important deactivation of the main cells producing collagen was observed both in rat and in human cells. These results suggest that anticoagulant and antioxidant treatment may be a potential therapeutical strategy for the treatment of portal hypertension in cirrhotic patients.
Esta tesis estudia el efecto de diferentes estrategias terapéuticas para el tratamiento de la hipertensión portal en models preclínicos de cirrosis. Se han estudiado los efectos de dos anticoagulantes (enoxaparina y rivaroxaban) y el efecto de un antioxidante dirigido a mitocondria (mitoquinona). En el primer estudio, se evaluó el efecto del anticoagulante enoxaparina en modelos preclínicos de cirrosis. Se observó que el tratamiento agudo con enoxaparina no afectó los parámetros sistémicos ni hemodinámicos evaluados. Tampoco modificó los niveles de GMPc o el contenido de estrés oxidativo hepático. El tratamiento a corto plazo (1 semana) disminuyó de manera significativa la presión portal en ratas cirróticas sin modificar el flujo. También disminuyó de manera significativa los niveles de estrés oxidativo y aumentó la biodisponibilidad de óxido nítrico (NO). Además, el tratamiento disminuyó un 26% la fibra hepática. Estos cambios se asociaron a una mejora del fenotipo de las células estrelladas hepáticas (CEH). También se observó una mejor en la microtrombosis hepática. El tratamiento a largo plazo (3 semanas) también disminuyó de manera significativa la presión portal en los dos modelos de cirrosis preclínica, sin cambios en los otros parámetros hemodinámicos. En este caso, también se observó una disminución del estrés oxidativo, pero sin mejora en la biodisponibilidad de NO. El tratamiento con enoxaparina redujo un 35% el área de fibrosis, cambios también asociados a una mejora del fenotipo de las CHE. También disminuyó el contenido de fibrina, mejorando así la microtrombosis hepática. Finalmente, también se observaron efectos beneficiosos en el modelo de prevención en ratas cirróticas por tioacetamida. La presión portal fue menor, en las ratas tratadas con enoxaparina, aunque los cambios no fueron tan marcados como en el modelo de regresión. También se redujo el área de fibrosis hepática, se mejoró el fenotipo de las CHE y hubo una menor microtrombosis hepática. En el segundo estudio, el anticoagulante oral anti factor Xa Rivaroxaban, disminuyó significativamente la presión portal en los dos modelos de cirrosis preclínica. La disminución de la presión portal no se asoció a cambios ni en el flujo sanguíneo portal ni en la presión arterial media, sugiriendo una disminución en la resistencia vascular intrahepática. Este hecho se confirmó ex vivo, donde se observó una disminución significativa de la resistencia vascular intrahepática del 35% en un sistema de perfusión con el flujo controlado. El tratamiento durante dos semanas disminuyó los niveles de estrés oxidativo, el número de células de Kupffer y aumentó la biodisponibilidad del NO. Las ratas tratadas con rivaroxaban tuvieron una mejor respuesta, aunque no significativa, al vasodilatador acetilcolina. Para confirmar el efecto beneficioso de rivaroxaban sobre el endotelio sinusoidal hepático, se evaluó el fenotipo de las células endoteliales sinusoidales y se observó una disminución en el marcador de activación, el factor von Willebrand, y una menor presencia de membrana basal. El tratamiento con rivaroxaban disminuyó el número y la activación de las CHE tanto a nivel de tejido como a nivel de célula aislada. No se observaron cambios en la apoptosis sugiriendo que el menor número de CHE vendría de una menor proliferación y no de un aumento en la muerte celular. Finalmente se observó que el tratamiento disminuía el contenido de fibrina sugiriendo una disminución de la microtrombosis hepática y se confirmó que los efectos de rivaroxaban sobre las CHE no era directos sino a través de la inhibición de la cascada de coagulación e inhibiendo la activación de los receptores PAR. En el tercer y último estudio se evaluó el efecto del tratamiento con un antioxidante dirigido a mitocondria. En un inicio se confirmó que en la cirrosis existe un aumento significativo de estrés oxidativo mitocondrial y que las principales células productores de éste estrés eran las CHE y los hepatocitos. El tratamiento con mitoquinona in vitro disminuyó significativamente el nivel de estrés oxidativo en todas las estirpes celulares hepáticas estudiadas. Además, disminuyó el nivel de activación de las CHE tanto de rata como humanas. Esto se confirmó en cortes ultrafinos de biopsias humanas y en líneas celulares. A nivel in vivo se observó que mitoquinona produjo un descenso significativo del nivel de estrés oxidativo hepático, tanto a nivel mitocondrial como total. A demás se disminuyó el contenido de proteínas nitrotirosinadas y la expresión génica de un factor inducido por el estrés oxidativo, Hif1a. Las ratas tratadas con mitoquinona tuvieron una disminución significativa de la presión portal y no se asoció a cambios ni en el flujo sanguíneo portal ni en la presión arterial media, sugiriendo una disminución en la resistencia vascular intrahepática. Mitoquinona también disminuyó el grado de fibrosis hepática y el nivel de activación de las CHE. Finalmente, se observó que el tratamiento con mitoquinona disminuyó significativamente el nivel de inflamación hepática. Para finalizar, esta tesis doctoral concluye que tanto el tratamiento con anticoagulantes, como el tratamiento con antioxidantes dirigidos a mitocondria pueden ser una potencial vía de tratamiento para la hipertensión portal en pacientes cirróticos.